Neurological Manifestations in Children Diagnosed With Inflammatory Bowel Disease

November 18, 2025 updated by: Bishoy Shehata Fahim

Neurological Manifestations in Children Diagnosed With Inflammatory Bowel Disease in Assiut University Child Hospital

screen for neurologic and psychiatric disorders in children and

adolescents with IBD.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Neurologic symptoms have a great importance in early diagnosis and

treatment preventing major morbidity and later sequelae, especially if they

precede GI symptoms

The prevalence of neurologic manifestations of IBD varies between 0.2% and

36%. Their pathogenesis of neurologic manifestations in IBD consists of 6

mechanisms: 1.malabsorption and nutritional deficiency 2.metabolic agents

3.infections complicating immune suppression 4.side effects of medications or

iatrogenic as a surgical complication 5.thromboembolism 6.immunological

factors

UC patients are similar to or higher than CD patients in the probability of

neurologic symptoms. Neurologic manifestations and complications include:

headache, dizziness, hypotonia, ADHD, tics, sensory complaints, seizures,

neuropsychiatric disorders, peripherial neuropathy, meningitis, vestibular

dysfunction, idiopathic IC hypertension, cerebral vasculitis, demyelinating

disorders and migraine

Study Type

Observational

Enrollment (Estimated)

44

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Children diagnosed with inflammatory bowel disease in Assiut university child hospital

Description

Inclusion Criteria:

  • patients with IBD aged from from 1 to18 years old.

Exclusion Criteria:

  • patients with IBD and aged above 18 years old or below 1 year old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Screening for Neurological manifestations among children diagnosed with inflammatory bowel disease in Assiut university children hospital
Time Frame: during the period from January 2026 to January 2027.

Neurologic symptoms have a great importance in early diagnosis and

treatment preventing major morbidity and later sequelae, especially if they

precede GI symptoms

The prevalence of neurologic manifestations of IBD varies between 0.2% and

36%. Their pathogenesis of neurologic manifestations in IBD consists of 6

mechanisms: 1.malabsorption and nutritional deficiency 2.metabolic agents

3.infections complicating immune suppression 4.side effects of medications or

iatrogenic as a surgical complication 5.thromboembolism 6.immunological

factors

UC patients are similar to or higher than CD patients in the probability of

neurologic symptoms. Neurologic manifestations and complications include:

headache, dizziness, hypotonia, ADHD, tics, sensory complaints, seizures,

neuropsychiatric disorders, peripherial neuropathy, meningitis, vestibular

dysfunction, idiopathic IC hypertension, cerebral vasculitis, demyelinating

disorders and migraine
during the period from January 2026 to January 2027.
screen for neurologic and psychiatric disorders in children and adolescents with IBD.
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bishoy Shehata Fahim

Investigators

  • Study Director: Nagla Hassan Abufaddan, Professor, Assiut university child hospital
  • Study Director: Randa Kandeel Abdelaleem, Lecturer, Assiut university child hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

November 18, 2025

First Submitted That Met QC Criteria

November 18, 2025

First Posted (Actual)

November 25, 2025

Study Record Updates

Last Update Posted (Actual)

November 25, 2025

Last Update Submitted That Met QC Criteria

November 18, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EIMs in Children with IBD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on IBD (Inflammatory Bowel Disease)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe